Therefore, considering the evidence describing the functional effects of DRD3 signalling on effector CD4+ T-cells, Treg, macrophages, and the results obtained here in CD8+ T-cells, it is tempting to speculate that treatment with selective DRD3 agonists should exert a therapeutic effect in tumour development. The gene discussed is CD4; the disease is neoplasm.